Biogen Idec

Elan closes Tysabri collaboration transaction with Biogen Idec

Wednesday, April 3, 2013 03:17 PM

Elan, a biotechnology company based in Ireland, has closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec, which was originally announced on February 6, 2013.

More... »

FDA approves Biogen Idec’s Tecfidera for multiple sclerosis

Friday, March 29, 2013 01:44 PM

The FDA has approved Biogen Idec’s Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis (MS).

More... »

Merck, Samsung Bioepis ink biosimilars development agreement

Friday, February 22, 2013 11:45 AM

Global healthcare company Merck and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, entered into an agreement to develop and commercialize multiple pre-specified and undisclosed biosimilar candidates.

More... »

Biogen Idec acquires full rights of Tysabri from Elan

Wednesday, February 6, 2013 11:41 AM

Biogen Idec, an independent biotechnology company, has agreed to purchase biotech Elan’s full strategic, commercial and decision-making rights to Tysabri.

More... »

Biogen Idec to discontinue development of ALS drug

Friday, January 4, 2013 10:29 AM

Weston, Mass.-based Biogen Idec has decided to discontinue development of dexpramipexole in amyotrophic lateral sclerosis (ALS), after top-line results of EMPOWER, its phase III trial, did not meet its primary endpoint, a joint rank analysis of function and survival, and no efficacy was seen in the individual components of function or survival.

More... »

Biogen Idec, Isis collaborate on antisense programs for neurological disorders

Monday, December 10, 2012 11:54 AM

Weston, Mass.-based Biogen Idec and Isis Pharmaceuticals of Carlsbad, Calif., have entered into a global collaboration agreement to discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders. Biogen Idec and Isis are already collaborating on antisense drugs to treat spinal muscular atrophy and myotonic dystrophy type 1 under previously established collaborations.

More... »

Nimbus Discovery names Lynch as executive chairman

Friday, November 2, 2012 03:04 PM

Nimbus Discovery, a biotechnology company based in Cambridge, Mass., has appointed Daniel S. Lynch to the company's board of directors as executive chairman. Lynch will succeed Bruce Booth, D. Phil., co-founder of Nimbus and partner at Atlas Venture, who will remain on the board.

More... »

Biogen Idec Foundation donates $100,000 to Teach for America STEM education

Monday, August 20, 2012 09:22 AM

The Biogen Idec Foundation andTeach For America have formed a new collaboration in support of Science, Technology, Engineering and Math (STEM) education.

More... »

Biogen Idec, Regulus to explore microRNA biomarkers for monitoring MS

Friday, August 17, 2012 11:38 AM

Regulus Therapeutics, a San Diego-based biopharmaceutical company focused on medicines targeting microRNAs, has entered into a collaboration with Biogen Idec to identify microRNAs as biomarkers for multiple sclerosis (MS).

More... »

Biogen Idec to collaborate to sequence genomes of ALS patients

Tuesday, July 17, 2012 02:54 PM

Biogen Idec has entered into a research collaboration with premier academic and research institutions to sequence the genomes of up to 1,000 patients with amyotrophic lateral sclerosis (ALS) in an effort to gain a deeper understanding about the fundamental genetic causes of ALS.

More... »